Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL-Reference-Cited by-同舟云学术

Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL

Published:2024-02 Issue:2 Volume:24 Page:83-93
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Rojek Alexandra E.^ORCID,Kline Justin P.,Feinberg Nicholas^ORCID,Appelbaum Daniel E.^ORCID,Pu Yonglin^ORCID,Derman Benjamin A.^ORCID,Jakubowiak Andrzej,Kosuri Satyajit,Liu Hongtao^ORCID,Nawas Mariam T.^ORCID,Smith Sonali M.,Bishop Michael R.,Riedell Peter A.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference39 articles.

1. GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany;Bethge;Blood,2022

2. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium;Nastoupil;J Clin Oncol,2020

3. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma;Pasquini;Blood Adv,2020

4. Axicabtagene Ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity;Jacobson;J Clin Oncol,2020

5. Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL;Gauthier;Blood,2022

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The prognostic utility of 18F-FDG PET parameters in lymphoma patients under CAR-T-cell therapy: a systematic review and meta-analysis;Frontiers in Immunology;2024-09-02

2. Metabolic tumor volume and the survival of patients with Non-Hodgkin lymphoma treated with chimeric antigen receptor T cell therapy: a meta-analysis;Frontiers in Immunology;2024-08-29

3. Circulating Tumor DNA as a Complementary Prognostic Biomarker during CAR-T Therapy in B-Cell Non-Hodgkin Lymphomas;Cancers;2024-05-15

4. SOHO State of the Art Updates and Next Questions Updates on Building Your CAR-T Cell Program;Clinical Lymphoma Myeloma and Leukemia;2024-03